{"id":"mfolfoxiri-adjuvant-chemotherapy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Nausea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It combines oxaliplatin, 5-fluorouracil, and irinotecan to inhibit DNA replication and induce apoptosis in cancer cells. This regimen is used in the treatment of colorectal cancer.","oneSentence":"mFOLFOXIRI is a combination chemotherapy regimen that targets rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:21.245Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of stage III colon cancer"}]},"trialDetails":[{"nctId":"NCT04338191","phase":"PHASE3","title":"mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-01","conditions":"Colorectal Cancer","enrollment":638},{"nctId":"NCT05427669","phase":"PHASE3","title":"Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)","status":"NOT_YET_RECRUITING","sponsor":"Yanhong Deng","startDate":"2022-10-09","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT05200299","phase":"PHASE2","title":"mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2022-02-01","conditions":"Colorectal Cancer","enrollment":100},{"nctId":"NCT05194878","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-12-01","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":840}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oxaliplatin","Irinotecan","Leucovorin","5-Fluorouracil"],"phase":"phase_3","status":"active","brandName":"mFOLFOXIRI adjuvant chemotherapy","genericName":"mFOLFOXIRI adjuvant chemotherapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"mFOLFOXIRI is a combination chemotherapy regimen that targets rapidly dividing cancer cells. Used for Adjuvant treatment of stage III colon cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}